CLINICAL TRIALS PROFILE FOR PALIPERIDONE PALMITATE

All Clinical Trials for PALIPERIDONE PALMITATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00073320 ↗	Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2003-08-01	The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
NCT00074477 ↗	Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2003-10-01	The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00101634 ↗	Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-12-01	The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00111189 ↗	A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.	Completed	Janssen-Cilag International NV	Phase 3	2005-02-01	The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00111189 ↗	A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2005-02-01	The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00119756 ↗	A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2005-06-01	The purpose of this study is to evaluate the safety and tolerability of intramuscular injections (to the buttocks or to the shoulders) of paliperidone palmitate in patients with schizophrenia.
NCT00210548 ↗	A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2005-04-01	The purpose of this study is to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia.

Clinical Trial Conditions for PALIPERIDONE PALMITATE

Condition Name

Condition Name for PALIPERIDONE PALMITATE
Intervention	Trials
Schizophrenia	54
Schizoaffective Disorder	2
Psychotic Disorders	2
Bipolar Disorder	2

Condition MeSH

Condition MeSH for PALIPERIDONE PALMITATE
Intervention	Trials
Schizophrenia	58
Psychotic Disorders	5
Disease	4
Recurrence	4

Clinical Trial Locations for PALIPERIDONE PALMITATE

Trials by Country

Trials by Country for PALIPERIDONE PALMITATE
Location	Trials
United States	250
Korea, Republic of	17
Spain	13
Germany	12
Ukraine	12

Trials by US State

Trials by US State for PALIPERIDONE PALMITATE
Location	Trials
California	20
Texas	17
Illinois	14
Florida	14
Ohio	12

Clinical Trial Progress for PALIPERIDONE PALMITATE

Clinical Trial Phase

Clinical Trial Phase for PALIPERIDONE PALMITATE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	15
Phase 3	25

Clinical Trial Status

Clinical Trial Status for PALIPERIDONE PALMITATE
Clinical Trial Phase	Trials
Completed	50
Recruiting	3
Withdrawn	2

Clinical Trial Sponsors for PALIPERIDONE PALMITATE

Sponsor Name

Sponsor Name for PALIPERIDONE PALMITATE
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	11
Janssen Scientific Affairs, LLC	6
Janssen Research & Development, LLC	6

Sponsor Type

Sponsor Type for PALIPERIDONE PALMITATE
Sponsor	Trials
Industry	53
Other	23
NIH	2

PALIPERIDONE PALMITATE Market Analysis and Financial Projection

Last updated: April 27, 2026

Paliperidone Palmitate: Clinical Trials Update, Market Analysis, and 2030 Projection

What is paliperidone palmitate in the market?

Paliperidone palmitate is an injectable long-acting antipsychotic (LAI) used to treat schizophrenia, with additional indication coverage depending on geography and product label. Commercially, it is marketed primarily as:

• Invega Sustenna (monthly formulation)
• Invega Trinza (3-month formulation)
• Invega Hafyera (6-month formulation, launched in multiple markets)

Across major markets, paliperidone palmitate LAIs compete on dosing convenience, time to steady exposure, clinician switching behavior, and access/reimbursement dynamics. In the US, the presence of multiple paliperidone palmitate dosing intervals supports line extensions and retention of treated cohorts.

Which clinical-trial themes matter for the next 24 months?

Clinical activity in paliperidone palmitate typically clusters around:

• Label expansions and regimen simplification (dose initiation/loading strategies, switching guidance, special populations)
• Real-world evidence generation embedded into post-authorization studies and registries
• Formulation or delivery program upgrades tied to dosing intervals and stability

However, producing a precise “clinical trials update” with correct trial identifiers (NCT numbers), enrollment status, endpoints, and readouts requires a complete, current trial-by-trial dataset. That dataset is not present in the input available for this request.

What is the current IP and patent landscape relevant to projections?

Paliperidone palmitate is protected by a combination of:

• Composition-of-matter patent families covering paliperidone and/or salt/formulation concepts
• Formulation and manufacturing-process patents
• Use and method-of-treatment claims, sometimes layered with jurisdiction-specific claim scopes
• Regulatory exclusivities (where applicable)

A credible market projection depends on when innovator-market exclusivity effectively ends and whether biosimilar or AB-generic equivalents are blocked by patent thickets. Without a defined, jurisdiction-specific patent inventory (US, EU, UK, key ex-China markets) and claim status dates, a precise forecast cannot be constructed under a rigorous patent-analytic standard.

What is the market size and growth outlook for paliperidone palmitate?

A market analysis requires at minimum:

• Global and regional sales (by product: Sustenna/Trinza/Hafyera)
• Competitor set benchmarking (other LAIs and branded oral comparators)
• Pricing and payer dynamics (tendering, exclusion lists, step edits)
• Conversion rates from oral to LAI and persistence curves

No current sales figures, payer policy data, or published market-research baselines were provided in the input for this request. As a result, generating hard numbers and a 2030 projection would be speculative.

What projections can be stated without inventing data?

No numeric projection for 2030 can be produced from the information supplied. A projection requires:

• starting market size and share
• expected penetration changes by interval (1-month, 3-month, 6-month)
• forecasted generic/biosimilar entry and patent-expiry timing
• macro and policy assumptions grounded in actual observed trends

Without these inputs, any quantified estimate would violate the requirement for factual accuracy.

---

Key Takeaways

• Paliperidone palmitate is an LAI franchise spanning monthly, 3-month, and 6-month dosing, supporting patient retention and prescriber preference for reduced visit frequency.
• A defensible clinical-trials update requires trial-level information (NCT IDs, endpoints, status, readouts) not present in the provided material.
• A credible market analysis and 2030 projection require validated sales baselines, regional breakdowns, and patent-expiry timelines not included in the input.
• Under a strict patent-analysis standard, no numeric clinical or market forecast can be issued from the available information.

---

FAQs

1) Is paliperidone palmitate only used for schizophrenia?

It is used for schizophrenia; label scope varies by jurisdiction and product. Clinical use patterns are driven by the marketed dosing intervals for LAI maintenance.

2) Why do the 1-month, 3-month, and 6-month formulations matter commercially?

They reduce injection frequency over time, which can improve adherence and persistence. That often supports higher lifetime value per treated cohort versus shorter-interval regimens.

3) What kinds of studies typically appear for paliperidone palmitate?

Common study types include conversion/switch studies, initiation regimen evaluations, special-population analyses, and post-authorization outcomes work.

4) How do patents affect the launch of competitors?

Competitors depend on whether they can clear formulation, process, method-of-treatment, and dosing-regimen claims, plus any regulatory exclusivities that extend effective market protection.

5) What is the minimum dataset needed to forecast to 2030 credibly?

A forecast needs starting sales (global and regional), expected dosing-interval mix changes, pricing/payer trajectory, and jurisdiction-specific patent expiry and litigation outcomes.

---

References

[1] FDA. Invega Sustenna (paliperidone palmitate) prescribing information. U.S. Food and Drug Administration.
[2] FDA. Invega Trinza (paliperidone palmitate) prescribing information. U.S. Food and Drug Administration.
[3] FDA. Invega Hafyera (paliperidone palmitate) prescribing information. U.S. Food and Drug Administration.